A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine
Authors:
- 21 March 2006
- journal article
- other
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (5) , 787-789
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Prevalence of resistance-associated mutations in newly diagnosed HIV-1 patients in GreeceVirus Research, 2005
- Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppressionThe Lancet, 2003
- Human Immunodeficiency Virus Type 1 Reverse‐Transcriptase and Protease Subtypes: Classification, Amino Acid Mutation Patterns, and Prevalence in a Northern California Clinic‐Based PopulationThe Journal of Infectious Diseases, 2001
- Evidence of Stavudine-Related Phenotypic Resistance Among Zidovudine-Pretreated HIV-1–Infected Subjects Receiving a Therapeutic Regimen of Stavudine Plus LamivudineJAIDS Journal of Acquired Immune Deficiency Syndromes, 1999
- Genotypic Resistance to Zidovudine as a Predictor of Failure of Subsequent Therapy with Human Immunodeficiency Virus Type-1 Nucleoside Reverse-Transcriptase InhibitorsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1999